5 Best Gene Therapy Stocks to Buy in 2026

2. Voyager Therapeutics Inc (NASDAQ:VYGR)

Stock Upside Potential: 252.57%

Number of Hedge Fund Holders: 17

Voyager Therapeutics Inc (NASDAQ:VYGR) is one of the best gene therapy stocks to buy in 2026. While the stock has risen only a modest 30% over the past year, analysts believe it can explode more than 250% over the next 12 months as the company advances its drug programs.

On May 13, Voyager Therapeutics announced that it presented preclinical data for its Alzheimer’s disease gene therapy, VY1706, at the American Society of Gene & Cell Therapy’s 2026 Annual Meeting in Boston.

Voyager’s VY1706 is a tau-silencing gene therapy. In testing in non-human primates, the therapy reduced tau protein in key brain regions by up to 64%. The treatment was also well-tolerated with no adverse events up to the highest dose.

With these solid results on hand, Voyager says it is on track to request FDA authorization for clinical testing of VY1706 in humans in Q2 2026. If the request is granted, the company projects first-in-human dosing with VY1706 in patients living with Alzheimer’s disease to occur in the back half of 2026.

Voyager is also advancing its VY7523 (anti-tau antibody) program and expects efficacy data from an ongoing trial in the back half of 2026. The company exited Q1 2026 with $172 million in cash and expects this to be enough to fund its programs into 2028.

Massachusetts-based Voyager Therapeutics Inc (NASDAQ:VYGR) is a biotechnology company developing gene therapies for diseases with unmet medical needs. It focuses on treatments for neurological diseases such as Alzheimer’s disease and Parkinson’s disease.